Traduction de «information contained » (Français → Néerlandais) :

TERMINOLOGIE

système d’information de chevet
informatiesysteem aan bed

système d’information de soins à domicile
thuiszorginformatiesysteem

système d’information de soins d’urgence
informatiesysteem voor spoedeisende hulp

informer les professionnels de la santé sur les résultats des tests de gaz sanguins artériels
informeren van zorgverlener over resultaat van arteriële bloedgasanalyse

logiciel d’application de système d’information financière de l’hôpital
applicatiesoftware voor informatiesysteem voor financiële administratie van een ziekenhuis

logiciel d’application de système d’information de chevet
applicatiesoftware voor informatiesysteem aan bed

informer les professionnels de la santé sur la présence d'un implant
informeren van zorgverlener over aanwezigheid van implantaat

système d’information de la banque du sang
bloedbankinformatiesysteem

informer les professionnels de la santé sur les résultats des tests
informeren van zorgverlener over testresultaat

système d’information de cardiologie
informatiesysteem voor cardiologie

TRADUCTIONS EN CONTEXTE

This information contained in this release is as of June 2, 2011, Pfizer assumes no obligation to update forward-looking statements contaiTned in this release as the result of new information or future events or developments. This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.
This release contains forward-looking information about a potential joint venture between Pfizer and Zhejiang Hisun Pharmaceuticals (Hisun) including, among other things, the anticipated benefits there of, that involves substantial risks and uncertainties.

DISCLOSURE NOTICE: The information contained in this release is as of December 12, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines.

This release contains forward-looking information that involves substantial risks and uncertainties regarding Prevenar 13, including its potential benefits; and the success of the AMC project for vaccines. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; whether and when regulatory authorities in countries where regulatory applications for Prevenar 13 may be pending or may be submitted will approve such applications and their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases.
DISCLOSURE NOTICE: The information contained in this release is as of December 13, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.
DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.